Showing 5201-5210 of 10220 results for "".
- Study: Itch and Rash Severity Linked to Biologic Use in Eczemahttps://practicaldermatology.com/news/itch-and-rash-severity-linked-to-biologic-use-in-eczema-paper/2484499/Data from a recent pre-proof in the Journal of the American Academy of Dermatology highlights that both itch and lesion severity independently predict biologic treatment initiation in patients with moderate-to-severe atopic de
- FDA Accepts sNDA for ZORYVE Cream 0.3% in Children Aged 2 to 5https://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-03-in-children-ages-25/2484497/The US Food and Drug Administration (FDA) has accepted Arcutis Biotherapeutics’ supplemental New Drug Application (sNDA) seeking an expanded indication for ZORYVE® (roflumilast) cream 0.3% to include children ages 2 to 5 with plaque psoriasis.
- Arcutis Completes Enrollment for INTEGUMENT-INFANT Studyhttps://practicaldermatology.com/news/arcutis-completes-enrollment-for-integument-infant-study/2484474/Arcutis Biotherapeutics announced the completion of patient enrollment for the INTEGUMENT-INFANT phase 2 study, according to a press release from the company. Researchers for INTEGUMENT-INFANT will be evaluating ZORYVE® (roflum
- Report: Antibiotics Linked to Shorter Biologic Persistence in Psoriasishttps://practicaldermatology.com/news/report-antibiotics-linked-to-shorter-biologic-persistence-in-psoriasis/2484451/Antibiotic exposure is associated with reduced persistence of biologic therapies in patients with psoriasis, according to findings from a nationwide French cohort study published in JAMA Dermatology.
- Remibrutinib Outperforms Placebo in Chronic Spontaneous Urticaria Control: Studyhttps://practicaldermatology.com/news/remibrutinib-outperforms-placebo-in-chronic-spontaneous-urticaria-control-study/2484429/Remibrutinib showed rapid and sustained efficacy in adults with chronic spontaneous urticaria (CSU) in a pooled analysis of the phase 3 REMIX-1 and REMIX-2 studies. The multicenter, double-blind, placebo-controlled trials looke
- Large Study Shows No Link Found Between Pemphigus and Psychiatric Disordershttps://practicaldermatology.com/news/large-study-shows-no-link-found-between-pemphigus-and-psychiatric-disorders/2484421/Results from a large retrospective cohort study analyzing more than 120 million U.S. electronic health records found no increased risk of psychiatric disorders in patients with pemphigus. "While 10–15% of dermatology patients ar
- Seborrheic Dermatitis Linked to Systemic Epithelial Barrier Diseases: Analysishttps://practicaldermatology.com/news/seborrheic-dermatitis-linked-to-systemic-epithelial-barrier-diseases-analysis/2484390/Findings from a new retrospective cohort suggest individuals living with seborrheic dermatitis are more likely to have other epithelial barrier diseases such as rosacea, alopecia areata, and celiac disease. Investigators publish
- FDA Warns Websites Selling Unapproved Botulinum Toxin Productshttps://practicaldermatology.com/news/fda-warns-websites-selling-unapproved-botulinum-toxin-products/2484341/The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including sym
- From ACAAI: Tapinarof Cream Shows Early Efficacy in Pediatric AD Regardless of Comorbiditieshttps://practicaldermatology.com/news/from-acaai-tapinarof-cream-shows-early-efficacy-in-pediatric-ad-regardless-of-comorbidities/2484383/New data from a pooled sub-analysis of the ADORING 1 and 2 trials show that VTAMA® (tapinarof) cream, 1%, was associated with improvements in children aged 2 to 17 with moderate to severe atopic dermatitis (AD). Results from th
- FDA Clears Ultherapy PRIME for Skin Laxity on Arms, Abdomenhttps://practicaldermatology.com/news/fda-clears-ultherapy-prime-for-skin-laxity-on-arms-abdomen/2484325/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME for the treatment of skin laxity on the anterior arms, posterior arms, and abdomen, according to Merz Aesthetics. The device is now FDA-cleared for noninvasive lifting and firming of the face, neck, décolleté, and body.